Friday, 16 October 2026European Markets

BARBARA BUI Stock Went Down By Over 28% In The Last 10 Sessions

Loading stream...

barbara bui, a renowned french women's clothing and accessories maker, witnessed a significant deflation in its share prices. over ten consecutive trading days, representing a staggering dip of 28.43%, the shares tumbled to eur7.30 on wednesday. this marked nearly three quarters lower than its 52-week high of eur10.50. interestingly, this downward trend coincided with the overarching trajectory of france's celebrated cac 40 stock market index, which also observed a 1% overall decrease, plummeting to eur7,331.73.

investment metrics and indicators

the price-to-earnings (p/e) ratio of barbara bui currently stands at 4.53. this means investors are paying eur4.53 for every eur1 of annual earnings. an important perspective is that a p/e ratio below 10 generally marks undervaluation. therefore, the recent declines have transformed the barbara bui shares into lucrative options for value investors who are in hunt of underpriced stocks.

return on equity and revenue growth

the return on equity (roe) of barbara bui stands noteworthy at 61.8%. this suggests strong profitability in relation to shareholders' equity. a higher roe percentage invariably shows the company's successful attempts in generating income from the invested capital. moreover, barbara bui registered a sparkling 7.9% year-on-year quarterly revenue growth over the bygone year. this culminated in a total revenue of 10.92 million euros, a fact that could provide some solace to its shareholders who had been witnessing their share price undergoing suffering due to the economic tantrums.

trading volumes

an important area of concern is the low trading volumes. barbara bui's most recent reported volume was only five shares. this marked an 86.11% decrease relative to its average volume of 36 shares. this may signal decreased interest and poses increased difficulties for shareholders in their attempts to sell shares hastily.

final remarks

overall, while barbara bui seems to be sailing in an uncertain stock market climate, its unswerving roe and revenue growth may provide a degree of comfort to existing shareholders. additionally, these factors could potentially lure bargain hunters in the market, casting a silver lining over the otherwise sober financial cloud.

more news about barbara bui (bui.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com